It has been demonstrated that lenalidomide causes selective degradation of IKZF1 (ikaros) and IKZF3 (aiolos) which are two essential transcription factors for myeloma cell proliferation \[[@CR1], [@CR2]\]. This anti-proliferative effect is mediated by downregulation of c-Myc and interferon regulatory factor 4 (IRF4) \[[@CR3]\]. In particular, IKZF3 regulates expression of IRF4 which is linked with lenalidomide activity \[[@CR4]--[@CR6]\]. However, the clinical relevance of IKZF1/IKZF3 expressions in myeloma patients has not been established. Thus, we examined nuclear expression of IKZF1/3 and its correlation with clinical outcomes in patients with relapsed/refractory MM who received lenalidomide therapy.

A total of 50 patients diagnosed with MM in our institution were entered in the study. All had received lenalidomide-based therapy (lenalidomide plus dexamethasone) after relapse. The median follow-up after diagnosis was 7.2 years. The relevant clinical and laboratory features are summarized in Table [1](#Tab1){ref-type="table"}.Table 1Clinical and laboratory features of MM patients treated with lenalidomideClinical featureTotal (*n* = 50)IKZF1 high expression (*n* = 36)IKZF1 low expression (*n* = 14)*P* valueIKZF3 high expression (*n* = 29)IKZF3 low expression (*n* = 21)*P* valueSex (M/F)31/1923/138/60.659019/1012/90.5471Age (year), median (range)59(41--75)57 (41--73)59 (45--75)0.641657 (41--69)59 (44--75)0.3105International staging system, no. (%)0.17850.1448 I24 (48)14 (38.89)10 (71.43)11 (37.93)13 (61.90) Il18 (36)14 (38.89)4 (28.57)11 (37.93)7 (33.33) III5 (10)5 (13.89)0 (0)5 (17.24)0 (0) NA3 (6)3 (8.33)0 (0)2 (6.90)1 (4.76)Hemoglobin concentration (g/L), median (range)105 (76--147)106 (76--147)103 (86--132)0.6027104 (76--147)107 (85--141)0.3121Calcium (mmol/L), median (range)2.25 (1.98--2.57)2.26 (1.98--2.57)2.23 (2--2.55)0.81622.25 (1.98--2.57)2.25 (2--2.55)0.7160Creatinine (μmol/L), median (range)76 (32--360)86 (40--360)67.58 (32--126)0.056988 (57--360)66 (32--126)0.0072Having lytic lesions, number of patients (%)27 (54)18 (50)9 (64.29)0.362812 (41.38)15 (71.43)0.0354B2-microglobulin (mg/L)3.08 (0.51--16.76)3.50 (0.51--16.76)2.96 (1.35--5.16)0.58173.62 (0.51--16.76)2.82 (1.07--5.16)0.1293Albumin (gr/L)40.5 (28--47)41 (28--47)39 (29--44)0.615141 (28--47)40 (29--44)0.9078Prior therapies, no. (%) ≥323 (46)15 (41.67)8 (57.14)0.324212 (41.38)11 (52.38)0.4411 Thalidomide29 (58)22 (61.11)7 (50)0.474815 (51.72)14 (66.67)0.2907 Bortezomib21 (42)14 (38.89)7 (50)0.474812 (41.38)9(42.86)0.9168 ASCT40 (80)31 (86.11)9 (64.29)0.118025 (86.21)15 (71.43)0.2859Response to lenalidomide plus dexamethasone, no. (%) Responsive41 (82)32 (88.89)9 (64.29)0.09428 (96.55)13 (61.90)0.0025 Non-responsive9 (18)4 (11.11)5 (35.71)1 (3.45)8 (38.1)Cytogenetics, no. (%)del (13q)1.00000.7243 Positive13 (26)9 (25)4 (28.57)7 (24.14)6 (28.57) Negative37 (74)27 (75)10 (71.43)22 (75.86)15 (71.43)del (17p)0.19660.2552 Positive8 (16)4 (11.11)4 (28.57)3 (10.34)5 (23.81) Negative42 (84)32 (89)10 (71.43)26 (89.66)16 (76.19)t(4;14)1.00000.7163 Positive9 (18)7 (19.44)2 (14.29)6 (20.69)3 (14.29) Negative41 (82)29 (80.56)12 (85.71)23 (79.31)18(85.71)amp(1q21)0.12280.1283 Positive20 (40)12 (33.33)8 (57.14)9 (31.03)11 (52.38) Negative30 (60)24 (66.67)6 (42.86)20(68.97)10 (47.62)

CD138 and IKZF1/3 immunohistochemical (IHC) staining were performed on the bone marrow aspiration/biopsy specimens taken before starting lenalidomide. CD138 positive myeloma cell aggregates (Additional file [1](#MOESM1){ref-type="media"}: Figure S1B) were examined for IKZF1/3 expression (Additional file [1](#MOESM1){ref-type="media"}: Figure S1C, D). H-score method (range 0--300) according to staining intensity and percentage of myeloma cells was applied. The median H-scores for IKZF1 and IKZF3 were 150 and 200, respectively, and high or low expression was based on above or below the median H-score (Fig. [1a](#Fig1){ref-type="fig"}).Fig. 1Expression of IKZF1 and IKZF3 proteins in tumor cells, measured by H-score (**a**) and their correlation with clinical response (**b**). Progression free survival (PFS) and overall survival (OS) in relation to IKZF1 nuclear expression (**c**, **d**), and in relation to IKZF3 nuclear expression (**e**, **f**) detected by IHC, respectively

Of the 50 MM cases, IKZF1 and IKZF3 were expressed in 36 (72%) and 29 (58%) cases, respectively. Twenty-eight of 29 cases (97%) with high IKZF3 expression also showed IKZF1 positivity (*P* \< 0.0001). High IKZF3 (*P* = 0.0025), but not IKZF1 expression (*P* = 0.094) was strongly correlated with clinical response (Fig. [1b](#Fig1){ref-type="fig"}). Patients with high IKZF1 or IKZF3 expression showed longer PFS (median 22.6 vs. 6.3 months, *P* = 0.0029; or 43.2 vs. 3.7 months; *P* \< 0.0001) and OS (median 44.3 vs. 12.1 months, *P* = 0.0014; or 47 vs. 12.1 months; *P* \< 0.0001) (Fig. [1c--f](#Fig1){ref-type="fig"}), respectively. In addition, the group with both high IKZF1/3 expression was associated with longer PFS (median 31.8 vs. 3.9 months, *P* \< 0.0001) and OS (median OS 58.7 vs. 12.1 months, *P* \< 0.0001), whereas the group with both low expression was correlated with shorter PFS (median 4.1 vs. 26.8 months, *P* = 0.0003) and OS (median 12.1 vs. 46.2 months, *P* = 0.0002). Of note, high IKZF3 expression appeared associated with higher creatinine but with less lytic lesion, and by multivariable analysis, high IKZF3 expression remained an independent poor risk factor for PFS (*P* \< 0.0001) and OS (*P* \< 0.0001) after adjusting these two covariates. There was no significant association between IKZF1/3 protein expression and other clinical or biological risk factors (Table [1](#Tab1){ref-type="table"}).

Previous studies have indicated controversial results about the relationship between Ikaros expression level and resistance to lenalidomide. Lu et al. \[[@CR7]\] found that some MM cell lines with higher expressions of IKZF1 or IKZF3 showed resistance to the drug; in contrast, Zhu et al. \[[@CR8]\] showed that low IKZF1 transcript levels were correlated with poor response to IMiDs. They also found that higher IKZF1 but not IKZF3 gene expression was associated with better OS. Our study demonstrates that expression of IKZF1/3 proteins (especially IKZF3) is correlated with better outcome in refractory MM patients treated with lenalidomide. A possible explanation for this observation is that in the presence of high IKZF1/3 levels, myeloma cells are more dependent on IKZF-associated signaling for proliferation. Particularly, IKZF3 is linked to plasma cell development and lenalidomide efficacy as IKZF3 is specifically required for the generation of long-lived plasma cells and it has been shown to be reduced by lenalidomide \[[@CR9], [@CR10]\].

To the best of our knowledge, this is the first report to show a correlation between IKZF1/3 protein expressions and clinical outcomes in refractory MM treated with lenalidomide. However, this study has limitations as it is retrospective with limited sample size. Nevertheless, as paraffin IHC is routinely available, robust, and inexpensive, if confirmed in a larger prospective study, IKZF1/3 (especially IKZF3) immunostaining can be readily adopted in clinical practice for prediction of drug response and clinical outcomes in MM patients receiving lenalidomide therapy.
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Additional file 1: Figure S1.Bone marrow biopsy from a patient with MM. (A) H&E stain, (B) CD138 for myeloma cells, (C) Nuclear expression of IKZF1, (D) Nuclear expression of IKZF3.
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